A Phase 1 Study to Evaluate the Relative Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Trial Profile

A Phase 1 Study to Evaluate the Relative Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2017

At a glance

  • Drugs Lofexidine (Primary)
  • Indications Drug dependence; Opioid abuse; Substance withdrawal syndrome
  • Focus Pharmacokinetics
  • Sponsors US WorldMeds
  • Most Recent Events

    • 04 Oct 2016 Status changed from recruiting to completed.
    • 20 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top